Placebo for BIIB080: artificial cerebrospinal fluid diluent
Sponsors
Biogen Idec Research Limited
Conditions
Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disease Dementia
Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
WithdrawnCTIS2022-501644-15-00
Target: 327Updated: 2023-02-20
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
Active, not recruitingCTIS2022-501644-15-01
Start: 2023-09-28Target: 233Updated: 2025-10-24